| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial JS De Bono, S Oudard, M Ozguroglu, S Hansen, JP Machiels, I Kocak, ... The Lancet 376 (9747), 1147-1154, 2010 | 4043 | 2010 |
| Alpha emitter radium-223 and survival in metastatic prostate cancer C Parker, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, SD Fossĺ, ... New England Journal of Medicine 369 (3), 213-223, 2013 | 3792 | 2013 |
| Olaparib for metastatic castration-resistant prostate cancer J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 382 (22), 2091-2102, 2020 | 1879 | 2020 |
| Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... New England Journal of Medicine 385 (12), 1091-1103, 2021 | 1643 | 2021 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402-1418, 2016 | 1417 | 2016 |
| Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ... Journal of Clinical Oncology 17 (11), 3461-3467, 1999 | 1144 | 1999 |
| Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project KR Carson, AM Evens, EA Richey, TM Habermann, D Focosi, JF Seymour, ... Blood, The Journal of the American Society of Hematology 113 (20), 4834-4840, 2009 | 1066 | 2009 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 872* | 2018 |
| Prostate specific antigen best practice statement: 2009 update KL Greene, PC Albertsen, RJ Babaian, HB Carter, PH Gann, M Han, ... The Journal of urology 189 (1), S2-S11, 2013 | 716 | 2013 |
| Radiation with or without antiandrogen therapy in recurrent prostate cancer WU Shipley, W Seiferheld, HR Lukka, PP Major, NM Heney, DJ Grignon, ... New England Journal of Medicine 376 (5), 417-428, 2017 | 669 | 2017 |
| Survival with olaparib in metastatic castration-resistant prostate cancer M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 383 (24), 2345-2357, 2020 | 652 | 2020 |
| Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind … O Sartor, R Coleman, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, ... The Lancet Oncology 15 (7), 738-746, 2014 | 565 | 2014 |
| Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. CL Bennett, MR Ferreira, TC Davis, J Kaplan, M Weinberger, T Kuzel, ... Journal of Clinical Oncology 16 (9), 3101-3104, 1998 | 530 | 1998 |
| Metastatic prostate cancer O Sartor, JS de Bono New England Journal of Medicine 378 (7), 645-657, 2018 | 523 | 2018 |
| Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a … P Hoskin, O Sartor, JM O'Sullivan, DC Johannessen, SI Helle, J Logue, ... The Lancet Oncology 15 (12), 1397-1406, 2014 | 493 | 2014 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 486 | 2021 |
| Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline IM Thompson, RK Valicenti, P Albertsen, BJ Davis, SL Goldenberg, ... The Journal of urology 190 (2), 441-449, 2013 | 468 | 2013 |
| Prostate cancer–major changes in the American Joint Committee on Cancer eighth edition cancer staging manual MK Buyyounouski, PL Choyke, JK McKenney, O Sartor, HM Sandler, ... CA: a cancer journal for clinicians 67 (3), 245-253, 2017 | 437 | 2017 |
| Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer W Xie, MM Regan, M Buyse, S Halabi, PW Kantoff, O Sartor, H Soule, ... Journal of Clinical Oncology 35 (27), 3097-3104, 2017 | 420 | 2017 |
| Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer O Sartor, RH Reid, PJ Hoskin, DP Quick, PJ Ell, RE Coleman, JA Kotler, ... Urology 63 (5), 940-945, 2004 | 417 | 2004 |
Johann de BonoInstitute of Cancer ResearchVerified email at icr.ac.uk
